NCT03883906

Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Children's Hospital Medical Center, Cincinnati · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to learn more about the use of viral specific T-lymphocytes (VSTs) to prevent viral infections that may happen after allogeneic stem cell transplant. Allogeneic means the stem cells come from another person. VSTs are cells specially designed to fight viral infections that may happen after a stem cell transplant (SCT). Stem cell transplant reduces your ability to fight infections. Viral infections are a common problem after transplant and can cause significant complications. Moreover, treatment of viral infections is expensive and time consuming, with families often administering prolonged treatments with intravenous anti-viral medications, or patients requiring prolonged admissions to the hospital. The medicines can also have side effects like damage to the kidneys or reduction in the blood counts, so in this study we are trying to find a way to prevent these infections.

Conditions

• Allogeneic Stem Cell Transplant
• Viral Infection

Interventions

Type	Name	Description
BIOLOGICAL	Viral Specific T-cells (VSTs)	VSTs will be infused into stem cell transplant recipients

Timeline

• Start date: 2019-03-16
• Primary completion: 2020-10-31
• Completion: 2021-10-01
• First posted: 2019-03-21
• Last updated: 2022-12-13
• Results posted: 2022-12-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study